Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras G12D mouse model

Diabetes

Volumn 61, Issue 5, 2012, Pages 1250-1262

  Gier, Belinda ^a   Matveyenko, Aleksey V ^a   Kirakossian, David ^a   Dawson, David ^a   Dry, Sarah M ^a   Butler, Peter C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; EXENDIN 4; K RAS PROTEIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DYSPLASIA; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PANCREAS CELL; PANCREAS DISEASE; PANCREAS DUCT; PANCREAS DYSPLASIA; PANCREAS METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; HOMEODOMAIN PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE; MUTATION; PANCREATIC DUCTS; PANCREATITIS; PEPTIDES; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; TRANS-ACTIVATORS; VENOMS;

EID: 84860567470     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1109     Document Type: Article

References (42)

1. Ebert R, Creutzfeldt W. Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev 1987;3:1-26 (Pubitemid 17002806)
2. Xu G, Kaneto H, Lopez-Avalos MD,Weir GC, Bonner-Weir S. GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract 2006;73:107-110 (Pubitemid 43765553)
3. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58:1604-1615
4. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-136
5. Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem Biophys Res Commun 2002;294:1-4 (Pubitemid 34687205)
6. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams- Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637 (Pubitemid 44912190)
7. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26: 2370-2377 (Pubitemid 36993328)
8. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
9. Ahmad SR, Swann, J . Exenatide and rare adverse events. N Engl J Med 2008;358:1970-1971; discussion 1971-1972
10. Ayoub WA, Kumar AA, Naguib HS, Taylor HC. Exenatide-induced acute pancreatitis. Endocr Pract 2010;16:80-83
11. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide: the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-777
12. Information for healthcare professionals: exenatide (marketed as Byetta): 8/2008 update. Available from http://www.fda.gov/Drugs/DrugSafety/Post marketDrugSafetyInformationforPatientsandProviders/ucm124713.htm. Accessed 21 December 2011
13. U.S. Food and Drug Administration, Department of Health and Human Services. Sitagliptin (marketed as Januvia and Janumet): acute pancreatitis. 2009. Available from http://www.fda.gov/Safety/MedWatch/Safety Information/SafetyAlertsforHumanMedicalProducts/ucm183800.htm. Accessed 21 December 2011
14. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13:559-566
15. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-4605 (Pubitemid 32055138)
16. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2009;53:153-159
17. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009;58:2148-2161
18. Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically-induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010;299:E1076-E1086
19. Strobel O, Rosow DE, Rakhlin EY, et al. Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology 2010;138:1166-1177
20. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026-1034 (Pubitemid 29226349)
21. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4: 437-450 (Pubitemid 38050041)
22. Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 26 October 2011 [Epub ahead of print]
23. Bai H., Li H., Zhang W, et al. Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/ Pdx1-Cre mice. Carcinogenesis 2011;32:1689-1696
24. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006;66:95-106 (Pubitemid 43166014)
25. Fendrich V, Chen NM, Neef M, et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010;59:630-637
26. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol 1996;148:1763-1770 (Pubitemid 26171674)
27. Ouyang H, Mou Lj, Luk C, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 2000;157: 1623-1631
28. Qian J, Niu J, Li M, Chiao PJ, Tsao MS. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 2005;65:5045-5053 (Pubitemid 40827312)
29. Matsuo Y, Campbell PM, Brekken RA, et al. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res 2009;7: 799-808
30. Jhala US, Canettieri G, Screaton RA, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003;17:1575-1580 (Pubitemid 36828785)
31. Arnette D, Gibson TB, Lawrence MC, et al. Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells. J Biol Chem 2003;278:32517-32525 (Pubitemid 37055689)
32. Friedrichsen BN, Neubauer N, Lee YC, et al. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006;188:481-492
33. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010;33:453-455
34. Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010;53:21-26
35. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-156
36. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-838
37. Gumbs AA. Obesity, pancreatitis, and pancreatic cancer. Obes Surg 2008; 18:1183-1187
38. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-488
39. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
40. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-990
41. Sipos B, Frank S, Gress T, Hahn S, Klöppel G. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 2009;9:45-54
42. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008;1:306-316